Platinum vs non‐platinum therapy: Tumour response
Platinum may leads to higher objective tumour response rate (OTRR) (assessable participants) compared with non‐platinum regimens (low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Platinum vs non‐platinum regimens Objective tumour response rate (OTRR) (assessable participants) · women with metastatic triple‐negative breast cancer (mTNBC) Platinum may leads to higher objective tumour response rate (OTRR) (assessable participants) compared with non‐platinum regimens (low certainty). Platinum‐containing regimens for triple‐negative metastatic breast cancer (2020) · Cochrane Headline outcomes only | RR 1.4 [1.22, 1.59] | 10 studies · 1205 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Platinum‐containing regimens for triple‐negative metastatic breast cancer 2020 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.